Einfluß des Cyclooxygenase-2-Inhibitors NS-398 auf Proliferation und Apoptose von OvarialkarzinomzellinienAntje Fürstenberg11231.11.1.14433#3331.1.251.1.361.1.47450#4081.1.5891.1.61.1.6.11011121.1.6.2131.1.6.3141.1.6.41.1.6.5151.1.71.1.7.1161.1.7.21.1.7.3171.2181.2.1192021221.2.21.323242242533.1263.23.33.4273.5283.629303.7313.8323.8.133311#1613.8.1.134294#1833.8.2297#185353.8.3294#184363.93.1037107#4816#2319#2319#2320#2363#2165#234374.1384.1.113#1913#1913#1913#1939415#59340472#5744.1.1.141497#3514.1.1.24213#19472#5564.1.243472#61213#1913#194.1.34445329#291516#280464.1.3.147599#3484.24.2.14.2.1.148623#7484.2.1.2495013#1913#1913#1951623#7484.2.252546#36353477#3984.34.3.154623#77415#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#164.3.255548#17715#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#1615#164.3.35613#19566#58655.15.1.15758595.1.2605.1.361625.1.4635.1.55.264656667685.369707172672737475LiteraturverzeichnisEidesstattliche ErklärungDanksagungdeInhaltsverzeichnisHilfe Literaturverzeichnis 1 Thun MJ et al. Aspirine use and reduced risk of fatal colon cancer. N Engl J Med 1991;325 : 1593 -1596 2 Giovannucci E et al. Aspirine use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-246 3 Giardello FM et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis . N Engl J Med 1993;328 (18): 1313-1316 4 Labayle D et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastoenterology 1991;101 (3):635-639 5 Celecoxib in oncology research. Clinical trials. Pharmacia Oncology Publication. October 2002. 6 Smith WL et al. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim Biophys Acta 1991;1083:1 -17 7 Dempke W. et al. Cyclooxygenase-2: a novel target for cancer chemotherapy ? J Cancer Res Clin Oncol 2001;127:411-417 8 Denkert et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002;160 (3):893-903 9 Smith WL et al. Prostaglandin and Thromboxan biosynthesis. Pharm Ther 1991;49:153 -179 10 Tjandrawinata RR et al. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997;75 (8):1111-1118 11 Qiao L et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1995;1258:215 -223 12 FitzGerald GA et al. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345 (6):433-442 13 Jones DA et al. Molecular Cloning of Human Prostaglandin Endoperoxide Synthase Type II and Demonstration of Expression in Response to Cytokines. J Biol Chem 1993;268 (12):9049-9054 14 Chandrasekharan NV et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA. 2002 Oct 15;99 (21):13926-31. Epub 2002 Sep 19. 15 Warner TD et al. Nonsteroidal drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA June 1999;96:7563 -7568 16 Phillips RK et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002 Jun;50 (6):857-860 17 Sano H et al. Expression of Cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-3789 18 Hida T et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58 (17):3761-3764 19 Achiwa H et al. Prognostic Significance of elevated Cyclooxygenase 2 expression in primary resected lung adenocarcinomas. Clin Cancer Res 1999;5 (5):1001-1005 20 Gupta S et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42 (1):73-78 21 Yip-Schneider et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000;21 (2):139-146 22 Lim HY et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000;6 (2):519-525 23 Chan G et al. Cyclooxygenase-2 expression is upregulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59 (5): 991-994 24 Oshima M et al. Suppression of Intestinal Polyposis in APC Knockout Mice by Inhibition of Cyclooxygenase-2 (COX-2). Cell 1996 Nov 29;87:803-809 25 Liu CH et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001 May 25;276 (21):18563-18569 26 Uefuji K et al. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 2001 Jan;76 (1):26-30 27 Masunaga R et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6(10):4064-4068 28 Khuri FR Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non.small cell lung cancer. Clin Cancer Res 2001;7( 4):861-867 29 Takahashi T et al. Increased expression of COX-2 in the development of human lung cancers. J Environ Pathol Toxicol Oncol 2002;21(2):177-181 30 Tsujii M et al. Alterations in cellular ahesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83(3):493-501 31 Uefuji K et al. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000;6(1):135-138 32 Rigas B et al. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993;122(5):489-490 33 Sheng H et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58(2):362-366 34 Chan TA et al. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc Natl Acad Sci,

USA

1998 ; 95:681 -686 35 Roberts RA et al. Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha). Carcinogenesis 1998;19:43-48 36 Tsubouchi Y et al. Inhibition of human lung cancer growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 2000;270:400-405 37 Gupta R et al. Prostacylin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci 2000;97:13275 -13280 38 He TC et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-345 39 Liu XH et al. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998;58(19):4245-4249 40 Hsu A et al. The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2. J Biol Chem 2000;275(15):11397-11403 41 Cao Y et al. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci

USA

2000;97:11280-11285 42 Scorrano L et al. Arachidonic acid causes cell death through the mitochondrial permeability transition. Implications for tumor necrosis factor-alpha apoptotic signaling. J Biol Chem 2001;276:12035 -12040 43 Steele VE et al. Potential use of lipoxygenase inhibitors for cancer chemoprevention. Expert Opin Investig Drugs 2000;9:2121-2138 44 Chang HC et al. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncology Reports 2001;8:1321 -1325 45 McGinty A et al. Cyclooxygenase-2 expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cell. J Biol Chem 2000;275(16):12095-12101 46 Chang YW et al. Cyclooxygenase 2 promotes cell survival by stimulation of dynein light chain expression and inhibition of neuronal nitric oxide synthase activity. Mol Cell Biol 2000 ; 20(22):8571-8579 47 Gilhooly EM et al. The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int J Oncol 1999;15(2):267-270 48 Majima M et al. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000;130(3):641-649 49 Tsujii M et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93(5):705-16 50 Takaoka Y, Niwa S, Nagai H. Interleukin-1beta induces interleukin-6 production through the production of prostaglandin E(2) in human osteoblasts, MG-63 cells. J Biochem (

Tokyo

) 1999;126(3):553-8 51 Nguyen M et al. Receptors and signaling mechanisms required for prostaglandin E2-mediated regulation of mast cell degranulation and IL-6 production. J Immunol 2002;169(8):4586-93 52 Huang SP et al. Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma. J Gastroenterol Hepatol 2002 Nov;17(11):1165-9 53 Daniel TO et al. Thromboxan A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 1999;59(18):4574-4577 54 Tsujii M et al. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci

USA

1997;94(7):3336-40 55 Nelson AR et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135 -1149 56 Kambayashi T et al. Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol 1995;154(7):3383-3390 57 Eling TE et al. Prostaglandin H synthase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol 1990; 30: 1-45 58 Elder DJE et al. Apoptosis induction and Cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the Cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int J Cancer 2000;86:553-560 59 Rhonda F et al. Selective Inhibition of Cyclooxygenase-2 Suppresses Growth and Induces Apoptosis in Human Esophageal Adenocarcinoma Cells. Cancer Res 2000;60:5767 -5772 60 Ming Li et al. Induction of Apoptosis by cyclooxygenase-2 inhibitor NS-398 through a cyctochrome c-dependent pathway in esophageal cancer cells. Int J Cancer 2001;93:218-223 61 Hida T et al. Cyclooxygenase-2 Inhibitor Induces Apoptosis and Enhances Cyctotoxicity of Various Anticancer Agents in Non-Small Cell Lung Cancer Cell Lines. Clin Cancer Res 2000;6:2006-2011 62 Uefuji K et al. Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines. Anticancer Res 2000;20 (6B):4279-4284 63 Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 2002;3:166 -173 64 Abiru S et al. Aspirin and NS-398 Inhibit Hepatocyte Growth Factor-Induced Invasiveness of Human Hepatoma Cells. Hepathology 2002;35:1117 -1124 65 Williams CS et al. A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia 2001;3(5):428-436 66 Hida T et al. Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res 1998;18(2A):775-782 67 Bae SH et al. Expression of Cyclooxygenase-2 (COX-2) in Hepatocellular Carcinoma and Growth Inhibition of Hepatoma Cell Lines by a COX-2 Inhibitor, NS-398. Clin Cancer Res 2001;7:1410-1418 68 Hanif R et al. Effects of nonsteroidal anti-inflammatpry drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52(2):237-245 69 Piazza GA et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997 Jul 15;57(14):2909-2915 70 Tegeder I et al. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001;15: 2057-2072 71 Sovak MA et al. Abberant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer . J Clin Invest 1997;100(12):2952-2960 72 Yamamoto Y et al. Sulindac inhibits activation of NFκB pathway. Biochem Pharmacol 1999;274(38):27307-27314 73 Grilli M et al. Neuroprotection by aspirin and sodium salicylate through blockade of NFκB activation. Science 1996;274:1383-1385 74 Murono S et al. Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res 2000;60:2555-2561 75 Yoshizaki T et al. The expression of matrix metalloproteinases 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci 1998;95:3621 -3626 76 Stark LA et al. Aspirin-induced activation of the NF-κB signaling pathway: a novel mechanism for Aspirin-mediated apoptosis in colon cancer cells. FASEB J. 2001;7:1273-1275 77 Jones R et al. Protein kinase B regulates T lymphoczyte survival, nuclear factor kappaB activation, and Bcl- X( L) levels in vivo. J Exp Med 2000;191:1721 -134 78 He TC et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-345 79 Su CG et al. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104(4):383-389 80 Li H et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan recptor TR3. Science 2000;289:1150-1164 81 Kang H et al. Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells. Biol Pharm Bull 2000;23:815 -819 82 Jemal A et al. Cancer Statistics, 2002. CA Cancer J Clin 2002;52:23-47 83 Robert Koch-Institut: Publikation "Entwicklung der Überlebensraten von Krebspatienten in Deutschland" 1999 84 Klimp A et al. Expression of Cyclooxygenase-2 and Inducible Nitric Oxide Synthase in Human Ovarian Tumors and Tumor-associated Macrophages. Cancer Res 2001 Oct1;61:7305 -7309 85 Ferrandina G et al. Cycloxygenase-2 (COX-2), Epidermal Growth Factor Receptor (EGFR), and Her-2/neu Expression in Ovarian Cancer. Gynecologic Oncology 2002;85:305 -310 86 Fairfield KM et al. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 2002 Aug;13(6):535-42 87 Cramer DW et al. Over the counter analgesics and risk of ovarian cancer. Lancet 1998;351(9096):104-107 88 Akhmedkhanov A et al. Aspirin and epithelial ovarian cancer. Prev Med 2001;33(6):682-687 89 Moysich KB et al. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10(8):903-6 90 Tavani A et al. Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol 2000; 11(9):1171-3 91 Rodriguez-Burford C et al. Effects of Nonsteroidal Anti-inflammatory Agents (NSAIDs) on Ovarian Carcinoma Cell Lines: Preclinical Evaluation of NSAIDs as Chemopreventive Agents. Clin Cancer Res 2002;8:202 -209 92 Cullen BR. RNA interference: antiviral defense and genetic tool. Nature Immunol 2002;3(7):597-599 93 Elbashir SM et al. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002;26(2):199-213 94 Elbashir SM et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494-498 95 Carsten Denkert, Antje Fürstenberg, Peter Daniel, Ines Koch, Martin Köbel, Wilko Weichert, Antje Siegert and Steffen Hauptmann. Induction of GO/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene. 2003 Nov 27;22(54):8653-61 96 Nicoletti I et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 1991;139:271 -279 97 Sachs L. Angewandte Statistik 9.Aufl. Springer-Verlag Berlin Heidelberg 1999:360-363 98 Lord E. The use of the range in place of the standard deviation in the t-test. Biometrica 1947;34:41 -67, Tab.10 99 Munkarah AR et al. Effects of Prostaglandin E2 on Proliferation and Apoptosis of Epithelial Ovarian Cancer Cells. J Soc Gynecol Investig 2002;9:168-73 100 Toyoshima T et al. Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21. Br J Cancer 2002;86:1150 -1156 101 Hung WC et al. Induction of p27KIP1 as a Mechanism Underlying NS398-Induced Growth Inhibition in Human Lung Cancer Cells. Mol Pharmacol 2000;58:1398 -1403 102 Yip-Schneider M et al. Cell Cycle Effects of Nonsteroidal Anti-Inflammatory Drugs and Enhanced Growth Inhibition in Combination with Gemcitabine in Pancreatic Carcinoma Cells. J Pharmacol Exp Ther 2001;298(3):976-985 103 Subbegowda R and Frommel TO. Aspirin Toxicity for Human Colonic Tumor Cells Results from Necrosis and Is Accompanied by Cell Cycle Arrest. Cancer Res 1998;58:2772-2776 104 Hurwitz A et al. Interleukin-1 is both morphogenic and cytotoxic to cultured ovarian cells: obligatory role for heterologous, contact-independent cell-cell interaction. Endocrinology 1992 Oct;131(4):1643-1649 105 Rieder J et al. Nitric oxide-dependent apoptosis in ovarian carcinoma cell lines. Gynecol Oncol 2001;82(1):172-176 106 Verschraegen CF et al. Effects of interleukin-1 alpha on ovarian carcinoma patients with recurrent disease. Eur J Cancer. 1996 Aug;32A(9):1609-1611 107 Windbichler GH et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000;82(6):1138-1144 108 Song X et al. Cyclooxygenase-2, Player or Spectator in Cyclooxygenase-2 Inhibitor-Induced Apoptosis in Prostate Cancer Cells. J National Cancer Institute 2002;94(8):585-591 109 Sherr CJ. Cancer Cell Cycle. Science. 1996;274(5293):1672-7 110 Smith ML et al. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanism of action. European Journal of Cancer 2000;36:664 -674 111 Moalic-Juge S et al. The anti-apoptotic property of NS-398 at high dose can be mediated in part through NF- κ B activation, hsp70 induction and a decrease in caspase-3 activity in human osteosarcoma cells. Int J Oncol 2002;20:1255-1262 112 Husain S et al. MAPK (ERK2) kinase – a key target for NSAIDs-induced inhibition of gastric cancer cell proliferation and growth. Life Sciences 2001;69:3045-3054 113 Trifan OC et al. Overexpression of Cyclooxygenase-2 Induces Cell Cycle Arrest. J Biol Chem 1999;274(48):34141-34147 114 Zahner G et al. Cyclooxygenase-2 overexpression inhibits platelet-derived growth factor induced mesangial cell proliferation through induction of the tumor suppressor gene p53 and the cyclin-dependent kinase inhibitors p21waf-1/cip-1 and p27kip-1. J Biol Chem 2002;277(12):9763-9771 115 Miwa Y et al. 15-Deoxy- Delta( 12,14)-prostaglandin J(2) induces G(1) arrest and differentiation marker expression in vascular smooth muscle cells. Mol Pharmacol 2000;58(4):837-844 116 Inoue H et al. Feedback control of cyclooxygenase-2 expression through PPARgamma. J Biol Chem 2000;275(36):28028-28032 117 Moalic S et al. Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor. Int J Oncol 2001;18(3):533-540 118 Tanaka A et al. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 2002;300(3):751-761 119 Law BK et al. Salicylate-induced Growth Arrest Is Associated with Inhibition of p70s6k and Down-regulation of c-Myc, Cyclin D1, Cyclin A, and Proliferating Cell Nuclear Antigen. J Biol Chem 2000;278(49):38261- 38267 120 Weiss H et al. Inhibition of store-operated Calcium entry contributes to the anti-proliferative effect of Non-steroidal Anti-Inflammatory Drugs in human colon cancer cells. Int J Cancer 2001;92:877-882 121 Swamy MV et al. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: A novel approach in developing effective chemopreventive regimens. Int J Oncol 2002;20:753-759 122 Pyo H et al. A Selective Cyclooxygenase-2 Inhibitor, NS-398, Enhances the Effect of Radiation in Vitro and in Vivo preferentially on the Cells That Express Cyclooxygenase-2. Clin Cancer Res 2001, Oct,7:2998 -3005 123 Zhang Z et al. Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology 2000 Jun;118(6):1012-1017 124 Camandola S et al. Pro-apoptotic action of PAR-4 involves inhibition of NF-kappaB activity and suppression of BCL-2 expression . J Neurosci Res 2000 Jul 15;61(2):134-139 125 Tamatani M et al. Tumor necrosis factor induces BCL-2 and BCL-x expression through NfkappaB activation in primary hippocampal neurons . J Biol Chem 1999 Mar;274(13):8531-8538